Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

6.655 -0.075 (-1.11%)
Streaming Delayed Price Updated: 10:49 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immix Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Other Serious Diseases Strategy
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Attends FDA CEO Forum in Washington DC
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.